The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2018 | Precision medicine for B-cell lymphomas
Up-and-coming mutation analyses are facilitating the precision treatment of lymphoma. Here, Jude Fitzgibbon, BA, PhD, of the Barts Cancer Institute, London, UK, discusses how mutations in EZH2, a histone methyltransferase gene, are likely to be present in around a quarter of lymphoma patients. Supporting this, Phase II trials in follicular lymphoma are suggestive of individuals with EZH2 mutations responding positively to EZH2 inhibitors. Prof. Fitzgibbon goes on to discuss the importance of utilizing the data that we have available to us, including whole exome data for diffuse large B-cell lymphoma (DLBCL). From this, we may able to discern the efficacy of treatments within different subsections of DLBCL – for instance, specific mutations within GCB and ABC DLBCL may correspond to poor treatment response. This video was recorded at the British Society for Haematology (BSH) 2018 Annual Meeting, held in Liverpool, UK.
